Prudential Financial Inc. trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 55.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 236,916 shares of the biotechnology company’s stock after selling 292,648 shares during the quarter. Prudential Financial Inc. owned about 0.55% of United Therapeutics Corporation worth $27,764,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Eagle Global Advisors LLC purchased a new position in shares of United Therapeutics Corporation in the second quarter worth about $206,000. TLP Group LLC purchased a new position in shares of United Therapeutics Corporation in the second quarter worth about $246,000. HPM Partners LLC raised its stake in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares during the last quarter. Fort L.P. raised its stake in shares of United Therapeutics Corporation by 5.2% in the second quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 99 shares during the last quarter. Finally, Prospera Financial Services Inc purchased a new position in United Therapeutics Corporation during the second quarter valued at approximately $277,000.

In other news, CEO Martine A. Rothblatt sold 1,260 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $121.46, for a total value of $153,039.60. Following the sale, the chief executive officer now directly owns 1,400 shares of the company’s stock, valued at $170,044. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,274 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total value of $147,873.18. Following the completion of the sale, the chief executive officer now directly owns 2,343 shares in the company, valued at $271,952.01. The disclosure for this sale can be found here. Insiders sold 16,818 shares of company stock valued at $2,071,702 over the last 90 days. Company insiders own 7.80% of the company’s stock.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at $120.22 on Thursday. The company has a market capitalization of $5,123.97, a P/E ratio of 10.46 and a beta of 1.38. United Therapeutics Corporation has a 12-month low of $112.01 and a 12-month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating the Zacks’ consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business earned $4.23 earnings per share. analysts forecast that United Therapeutics Corporation will post 11.92 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://theolympiareport.com/2017/11/16/united-therapeutics-corporation-uthr-shares-sold-by-prudential-financial-inc.html.

Several brokerages recently weighed in on UTHR. Cowen and Company reiterated a “hold” rating and set a $129.00 price target on shares of United Therapeutics Corporation in a research report on Friday, October 27th. HC Wainwright reiterated a “hold” rating and set a $95.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, October 26th. Zacks Investment Research upgraded United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. TheStreet cut United Therapeutics Corporation from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Finally, ValuEngine upgraded United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $132.82.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.